Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680266 | 0.82 | CYP2A6 (0.49) | GRM5GRM4USP30 | |
| SCHEMBL1682507 | 0.81 | CA12 (0.47) | GAAHPGDSALKBH2GRM5MAPT | |
| SCHEMBL28241532 | 0.81 | MAOB (0.39) | GAAGRM5USP30 | |
| SCHEMBL31158430 | 0.81 | GAA (0.53) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL2645514 | 0.80 | GRM5 (0.48) | GRM5TSHRMAPTDRD2DRD3 | |
| SCHEMBL21525502 | 0.80 | HPGDS (0.53) | HPGDSALKBH2 | |
| SCHEMBL6851887 | 0.78 | GAA (0.50) | GAAHPGDSALKBH2NPC1RAB9A | |
| SCHEMBL19928288 | 0.78 | GRM5 (0.50) | GAAGRM5TSHRGRM4HTR2B | |
| SCHEMBL21753342 | 0.78 | CYP19A1 (0.40) | GRM5ACACB | |
| SCHEMBL21753378 | 0.78 | ALDH1A1 (0.47) | GRM5NPC1RAB9ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120585827-A | Application of compound in preparation of medicine for resisting cryptosporidium parvum | 华南农业大学 | 2025-09-05 | — | — | CN | disclosed |
| CN-118161459-A | Solid dispersion of cryptosporidium parvum-resistant compound, and preparation method and application thereof | 华南农业大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| CN-113200978-B | Isothia (selenium) azolone derivative and application thereof in anti-coronavirus drugs | 中国海洋大学 | 2022-09-16 | — | — | CN | disclosed |
| US-10336731-B2 | Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-02 | — | — | US | disclosed |
| CN-108329246-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-07-27 | — | — | CN | disclosed |
| CN-105130967-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017048612-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015143653-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2341775-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| CN-100393299-C | Use of an inhibitor of 15-hydroxyprostaglandin dehydrogenasein order to stimulate pigmentation of the skin or skin appendages | OREAL (FR) | 2008-06-11 | — | — | CN | disclosed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| CN-1774229-A | Use of an inhibitor of 15-hydroxyprostaglandin dehydrogenasein order to stimulate pigmentation of the skin or skin appendages | OREAL (FR) | 2006-05-17 | — | — | CN | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336731-B2 | Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors | TPH1, TPH2, IDO1 | GAA 3037/4885HPGDS 2224/4885ALKBH2 278/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | GAA 1962/4885HPGDS 1388/4885ALKBH2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.